CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Position Raised by ARK Investment Management LLC

ARK Investment Management LLC increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 19.7% during the 4th quarter, HoldingsChannel reports. The firm owned 8,973,064 shares of the company’s stock after buying an additional 1,474,439 shares during the period. CRISPR Therapeutics comprises 2.9% of ARK Investment Management LLC’s holdings, making the stock its 9th largest position. ARK Investment Management LLC owned approximately 0.11% of CRISPR Therapeutics worth $353,180,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRSP. International Assets Investment Management LLC purchased a new stake in CRISPR Therapeutics in the third quarter worth approximately $1,825,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of CRISPR Therapeutics by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,080 shares of the company’s stock worth $146,000 after acquiring an additional 545 shares during the last quarter. Arkadios Wealth Advisors boosted its stake in shares of CRISPR Therapeutics by 4.9% during the 3rd quarter. Arkadios Wealth Advisors now owns 11,295 shares of the company’s stock worth $531,000 after acquiring an additional 524 shares during the last quarter. SFE Investment Counsel boosted its stake in shares of CRISPR Therapeutics by 8.0% during the 3rd quarter. SFE Investment Counsel now owns 6,312 shares of the company’s stock worth $297,000 after acquiring an additional 466 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of CRISPR Therapeutics by 64.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,381 shares of the company’s stock worth $770,000 after acquiring an additional 6,405 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP opened at $44.51 on Wednesday. The company has a market cap of $3.82 billion, a P/E ratio of -10.19 and a beta of 1.67. The firm’s fifty day moving average is $42.29 and its two-hundred day moving average is $46.00. CRISPR Therapeutics AG has a 52-week low of $36.52 and a 52-week high of $90.62.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRSP has been the topic of several analyst reports. The Goldman Sachs Group dropped their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Bank of America dropped their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Chardan Capital dropped their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Stifel Nicolaus dropped their price target on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research note on Thursday, February 13th. Finally, TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective on the stock in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $74.40.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.